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MCP-1 is up-regulated in unstressed and stressed HO-1 knock-
out mice: Pathophysiologic correlates.
Background. Up-regulation of heme oxygenase-1 (HO-1) oc-
curs in, and often confers protection to, the injured kidney.
Up-regulation of monocyte chemoattractant protein-1 (MCP-
1) promotes not only acute and chronic nephritides but also
acute ischemic and nephrotoxic injury. The present study was
stimulated by the hypothesis that expression of MCP-1 is sup-
pressed by HO-1, and analyzed the effect of HO-1 on the ex-
pression of MCP-1 in stressed and unstressed conditions.
Methods. Expression of MCP-1 and pathophysiologic corre-
lates were examined in HO-1 knockout (HO-1−/−) and wild-
type (HO-1+/+) mice in the unstressed state in young and aged
mice, and following nephrotoxic and ischemic insults.
Results. In unstressed HO-1−/− mice, plasma levels of MCP-
1 protein were elevated, and MCP-1 mRNA expression was in-
creased in circulating leukocytes and in the kidney. Such early
and heightened up-regulation of MCP-1 was eventually accom-
panied by phenotypic changes in the aged kidney consistent
with MCP-1, namely, proliferative changes in glomeruli, tubu-
lointerstitial disease, and up-regulation of transforming growth
factor-b1 (TGF-b1) and collagens I, III, and IV. In response to a
nephrotoxic insult such as hemoglobin, MCP-1 mRNA was up-
regulated in a markedly sustained manner in HO-1−/− mice.
In response to a duration of ischemia that exerted little effect in
HO-1+/+ mice, HO-1−/− mice exhibited higher expression of
MCP-1 mRNA, enhanced activation of nuclear factor-jB (NF-
jB) (the transcription factor that regulates MCP-1), markedly
greater functional and structural renal injury, increased caspase-
3 expression, and increased mortality.
Conclusion. In the absence of HO-1, expression of MCP-
1 is significantly and consistently enhanced in unstressed and
stressed conditions. We speculate that the protective effects of
HO-1 in injured tissue may involve, at least in part, the capacity
of HO-1 to restrain up-regulation of MCP-1.
1See Editorial by Kanwar, p. 896.
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Heme oxygenase (HO) represents the dominant mech-
anism whereby heme is degraded, facilitating as it does,
the conversion of heme to biliverdin, in the course of
which, iron is released and carbon monoxide is emit-
ted; biliverdin is subsequently converted to bilirubin by
biliverdin reductase [1–4]. HO-1 is the isoform rapidly
and robustly responsive to a wide range of stimuli,
including those that are ischemic, nephrotoxic, and in-
flammatory in origin [1–5]. Such induction of HO-1 in
the kidney and other tissues exposed to such insults of-
ten confers salutary effects through mechanisms that in-
clude the following: the quenching of oxidative stress
[1–4]; the sequestration and extracellular transport of
iron [5, 6]; the generation of anti-inflammatory, antiox-
idant metabolites such as bilirubin [7, 8]; the production
of carbon monoxide, the latter exerting antiapoptotic and
anti-inflammatory actions [9, 10]; and the accompanying
up-regulation of cell cycle inhibitors such as p21 [11, 12].
Our prior studies raised the possibility that the cytopro-
tective, anti-inflammatory effects of HO-1 may involve
suppressive effects of HO-1 on the expression of mono-
cyte chemoattractant protein-1 (MCP-1) [13]. In addition
to serving as one of the most potent chemoattractants
ever described for monocytes, MCP-1 recruits memory
T cells and natural killer cells, exerts proinflammatory
and procoagulant effects, activates the endothelium, and
fosters the proliferation and migration of smooth mus-
cle cells [14, 15]. These actions of MCP-1 underlie its
active participation in diverse inflammatory conditions,
atherosclerosis, and assorted vasculopathies. Increased
expression of MCP-1 in the kidney, and elevated concen-
trations of MCP-1 in serum and urine, also contribute to
acute and chronic nephritides [16–20]. The involvement
of MCP-1 in tissue injury in general, and in the kidney in
particular, however, is not limited to inflammatory states,
but indeed extends, as recently demonstrated, to acute is-
chemic and toxic insults [21–25]. For example, MCP-1 is
rapidly induced in the kidney following renal ischemia
[21, 22], and based on diverse approaches—studies
utilizing MCP-1 receptor (CCR2) knockout mice [23],
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novel inhibitors of MCP-1 [24], and novel strategies that
inhibit activation of transcription factors [nuclear factor-
jB (NF-jB)] which induce MCP-1 [22]—the evidence is
strong that such up-regulation of MCP-1 is a significant
determinant of acute ischemic renal injury.
In our prior studies of chronic tubulointerstitial inflam-
mation induced by repetitive exposure to heme proteins
[13], HO-1−/− mice exhibited distinctly greater mononu-
clear cellular infiltration in the kidney accompanied by
more marked MCP-1 expression. While these observa-
tions suggest the possibility that in HO-1−/− mice the
absence of inducible HO-1 in response to heme provokes
increased expression of MCP-1, this markedly greater ex-
pression of MCP-1 in HO-1−/− mice may simply reflect
the much more severe mononuclear cellular infiltration
in the kidneys of HO-1−/− mice. Our subsequent stud-
ies utilized an in vitro cellular system to analyze the in-
volvement of HO activity in heme-induced up-regulation
of MCP-1 [26]. In these in vitro studies, heme induced
MCP-1 as well as HO-1. Inhibition of HO activity pre-
vented expression of MCP-1 observed at a relatively early
time point, whereas continued inhibition of HO activity
in heme-treated cells led to a more delayed and sustained
up-regulation of MCP-1. From these in vitro studies, we
concluded that heme-induced up-regulation of MCP-1 in
vitro is complex, involving seemingly contrasting effects
of HO activity. HO activity contributes to the early in-
duction of MCP-1 by heme; in contrast, continued HO
activity prevents the delayed up-regulation of MCP-1 in
response to heme.
Given the overriding importance of MCP-1 as a de-
terminant of renal injury arising from inflammatory, is-
chemic, and toxic insults, and the possibility that HO-1
may limit the extent of such injury by influencing the
expression of MCP-1, the present studies further ana-
lyzed this interaction of HO-1 and MCP-1 using the HO-
1−/− mouse in the unstressed and stressed state. We rea-
soned that if MCP-1 is inhibited by HO-1 then examin-
ing the expression of MCP-1 in an unstressed HO-1−/−
mouse may offer insights regarding the effect of HO-1 on
the prevailing expression of MCP-1. Additionally, given
the recognition of the importance of MCP-1 in toxic and
ischemic insults, we examined the effect of these insults
on MCP-1 expression in HO-1+/+ and HO-1−/− mice.
METHODS
Studies in HO-1+/+ and HO-1−/− mice
The HO-1−/− model. Homozygous HO-1 null mutant
mice, employed in this and prior studies by this laboratory
[13, 27], were generated by targeted disruption of the HO-
1 gene as described by Poss and Tonegawa [28]. Colonies
of mice were maintained by breeding HO-1−/− males
with HO-1+/− females. Offspring were genotyped at the
time of weaning by using polymerase chain reaction to
amplify the wild-type and mutant alleles of genomic DNA
from tail samples. HO-1+/+ mice were used as controls.
For all experiments, HO-1+/+ and HO-1−/− mice were
age-matched, and mice from 7 to 70 weeks were utilized.
Baseline studies. A cohort of relatively young, un-
stressed HO-1+/+ and HO-1−/− mice was sacrificed for
baseline assessment of the expression of MCP-1 and for
histologic examination of hematoxylin and eosin–stained
sections from formalin-fixed, paraffin-embedded kidney
tissues. Mononuclear cells were also isolated from blood
from these animals on a ficoll gradient as previously
described [29]. Briefly, whole blood was diluted in an
equal volume of Hanks balanced salt solution and layered
on ficoll (Ficoll-Paque Plus) (Amersham Biosciences,
Piscataway, NJ, USA). After centrifugation at 400 × g
for 30 minutes, the buffy layer was removed and washed
twice in phosphate-buffered saline (PBS). Total RNA was
extracted from the resulting pellet of mononuclear cells
as described below.
Nephrotoxic insult: Administration of hemoglobin.
Rat hemoglobin was administered to HO-1+/+ and
HO-1−/− mice, as previously employed by our labora-
tory [13]. Briefly, mice were deprived of water overnight
for 16 hours but allowed free access to rodent chow.
The following day, rat hemoglobin (90 mg/100 g body
weight) (Sigma Chemical Co., St. Louis, MO, USA) or
sterile saline vehicle was administered via tail vein injec-
tion to both HO-1+/+ and HO-1−/− mice. Eight hours
or 3 days later, mice were sacrificed for examination
of renal MCP-1 mRNA expression. In a related study,
HO-1+/+ and HO-1−/− mice were subjected to either
a tail vein injection of sterile saline (0.1 mL/10 g body
weight) or a sham needle stick after overnight dehydra-
tion. Eight hours later, mice were sacrificed for examina-
tion of MCP-1 expression as described above.
Renal ischemia/reperfusion (I/R) injury. Renal is-
chemia was imposed in HO-1+/+ and HO-1−/− mice
by bilateral and total occlusion of the renal arteries un-
der pentobarbital anesthesia [30, 31]. The procedure was
performed on a heated surface to ensure maintenance of
normal body temperature. The kidneys were exposed via
a midline abdominal incision and the renal pedicles care-
fully dissected. The pedicles were clamped bilaterally for
15 minutes using nontraumatic sterile clamps (RS5426,
Micro Aneurysm clip, straight, 10 mm, 125 g pressure)
(Roboz Surgical Instruments, Rockville, MD, USA). A
sham procedure in HO-1+/+ and HO-1−/− mice in-
cluded anesthesia and laparotomy but omitted dissection
or clamping of the renal pedicle. Following removal of
the renal clamps (applied for 15 minutes), the abdominal
wall was sutured. At day 1 after I/R injury, renal func-
tion was assessed by measurement of plasma creatinine
and blood urea nitrogen (BUN) using a Creatinine Ana-
lyzer 2 and a BUN Analyzer 2, respectively (Beckman
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Table 1. Primers and probes used for quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR)
Gene Primer/Probe Sequence
MCP-1 Forward 5′-GGCTCAGCCAGATGCAGTTAA-3′
Reverse 5′-CCTACTCATTGGGATCATCTTGCT-3′
TaqMan 5′-(FAM) CCCCACTCACCTGCTGCTACTCATTCAC (TAMRA)-3′
18S Forward 5′-TGTCTCAAAGATTAAGCCATGCAT-3′
Reverse 5′-AACCATAACTGATTTAATGAGCCATTC-3′
TaqMan 5′-(VIC) TACGCACGGCCGGTACAGTGAAACT (TAMRA)-3′
MCP-1 is monocyte chemoattractant protein-1.
Instruments, Fullerton, CA, USA). The kidneys were
harvested from mice sacrificed at 1 hour, 1 day, or 7 days
after renal I/R. A semiquantitative score for renal injury
was undertaken in kidneys harvested at day 1 and day 7.
Scores of 1+, 2+, or 3+ were assigned to kidney sections
demonstrating 10%, 10% to 25%, and >25% of tubules
to be dilated; the cortex and medulla were separately
scored. Tubular necrosis was scored as the percentage
of tubules demonstrating any evidence of epithelial cell
necrosis.
Studies of aged HO-1+/+ and HO-1−/− mice. Ad-
ditional cohorts of HO-1+/+ and HO-1−/− mice were
sacrificed at 70 weeks at which time point the kidneys
were harvested for studies of renal histology, electron
microscopy, and gene expression [collagens I, III, IV,
and transforming growth factor-b1 (TGF-b1)] by North-
ern analysis using rat cDNAs for all genes as previously
described [32].
Assessment of expression of MCP-1
RNA extraction and Northern analysis. Total RNA was
extracted from tissue and mononuclear cells using the
Trizol (Invitrogen, Carlsbad, CA, USA) technique.
Twenty micrograms of total RNA from each kidney sam-
ple were separated on an agarose gel and transferred to a
nylon membrane. Membranes were hybridized overnight
with a 32P-labeled rat cDNA probe for MCP-1. Autora-
diograms were standardized, as previously described [32],
by factoring the optical density of the message for MCP-
1 with the optical density of the 18S rRNA, the latter
obtained on a negative of the ethidium bromide–stained
nylon membrane.
Measurement of MCP-1 mRNA expression by quan-
titative real-time reverse transcription-polymerase chain
reaction (RT-PCR). Expression of MCP-1 mRNA was
determined from total RNA extracted from kidneys
and mononuclear cells as described above. The analy-
sis was performed on an ABI Prism 7000 by a one-step
method using TaqMan One-Step RT-PCR Mastermix
reagents (Applied Biosystems, Foster City, CA, USA).
The primers and probes were designed using Primer Ex-
press software (Applied Biosystems). The sequences of
primers and TaqMan probes are listed in Table 1. Each
reaction was performed in duplicate in a total reaction
volume of 25 lL; primer and probe concentrations were
300 nmol/L and 200 nmol/L, respectively, and reactions
contained between 10 and 100 ng of total RNA. Condi-
tions of quantitative real-time RT-PCR were as follows:
30 minutes at 48◦C (RT), 10 minutes at 95◦C (RT in-
activation and initial activation), and then 40 cycles of
amplification for 15 seconds at 95◦C (denaturation) and
1 minute at 60◦C (annealing and extension).
Standard curves were constructed for both 18S and
MCP-1 using tenfold serial dilutions of cDNA which were
generated by PCR on normal mouse kidney RNA using
the primers in Table 1. The slopes of these standard curves
were used to calculate efficiency [(2 − 10(1/−slope)) × 100]
of the PCR reactions, as described previously [33], and ef-
ficiencies between 95% and 105% were accepted. Each
96-well plate contained standard curves for 18S and MCP-
1, and all samples were measured in duplicate for both
18S and MCP-1. Expression of 18S rRNA was used to
correct for differences in quantities of RNA per reaction
and to compensate for any possible inhibition of either
reverse transcription or PCR. Results are expressed as a
ratio of MCP-1 to 18S expression.
Measurement of plasma MCP-1 by enzyme-linked im-
munosorbent assay (ELISA). Concentrations of MCP-1
protein in the plasma of mice were measured employ-
ing an ELISA kit (2665KI) (BD Pharmingen, San Diego,
CA, USA).
Western analysis for expression of active caspase-3
Kidney tissue was homogenized in a buffer consist-
ing of PBS containing 1% Igepal CA-630, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate (SDS)
(Bio-Rad, Hercules, CA, USA) and a cocktail of protease
inhibitors (Complete, Roche, Indianapolis, IN, USA).
Homogenates were incubated on ice with occasional ag-
itation for 90 minutes. Western blot analyses were per-
formed as described in detail in our prior publications
[11, 27]. Briefly, 100 lg protein aliquots were separated
on 15% Tris HCl gels and transferred to polyvinyli-
dene difluoride (PVDF) membranes. A mouse mono-
clonal primary antibody for caspase-3 (C76920-150, BD)
(Transduction, San Diego, CA, USA) was employed and
followed by a horseradish peroxidase–conjugated, goat
antimouse polyclonal secondary antibody (StressGen,
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Fig. 1. Up-regulation of MCP-1 in HO-1 −/− mice. (Left) Plasma MCP-1 concentration in HO-1 +/+ and HO-1−/− mice. In these and subsequent
figures, data are presented as mean ± SEM, and ∗ represents P < 0.05. (Right) Expression of MCP-1 mRNA by quantitative real-time RT-PCR in
circulating leukocytes in HO-1+/+ and HO-1−/− mice. Results are expressed as a ratio of MCP-1 mRNA to 18S expression.
Victoria, BC, Canada). Equivalency of loading of West-
ern blot analyses was assessed using a rabbit polyclonal
b-actin antibody (A-2006) (Sigma Chemical Co.). De-
tection was achieved using a chemiluminescence method
(Amersham Pharmacia).
Assessment of NF-jB activation by electrophoretic
mobility shift assay (EMSA)
An EMSA was performed to assess activation of NF-
jB in renal tissues from HO-1+/+ and HO-1−/− mice.
Nuclear protein extracts were prepared from kidney
tissues as previously described by this laboratory [13].
Ten micrograms of this protein extract were incubated
with 4 lL of binding buffer [5 mmol/L MgCl2, 50 mmol/L
Tris-HCl, pH 7.5, 250 mmol/L NaCl, 20% glycerol, 2.5
mmol/L ethylenediaminetetraacetic acid (EDTA), 2.5
mmol/L dithiothreitol (DTT), and 0.25 mg/mL poly
dI.dC] and 30,000 CPM of 32P-labeled NF-jB probe.
The oligonucleotide employed corresponded to the two
NF-jB binding sequences present within the enhancer
of the human immunodeficiency virus (HIV) LTR (5′-
ACAAGGGACTTTCCGCTGGGGACTTTCCAGGG
A-3′), labeled with [32P] adenosine triphosphate (ATP).
Termination was effected after 30 minutes with 2 lL
of gel-loading buffer (250 mmol/L Tris-HCl, pH 7.5,
0.2% bromophenol blue, and 40% glycerol). The
binding reaction was analyzed by electrophoresis in a
nondenaturing 7% polyacrylamide gel and visualized by
autoradiography.
Statistics
Results are expressed as mean ± SEM. For com-
parisons involving two groups, the Student t test
was employed while for comparisons involving more
than two groups, ANOVA was employed followed by
Student-Neumann-Keuls test. Mortality was assessed by
Fisher’s exact test. Results are considered significant for
P < 0.05.
RESULTS
Studies in mice 30 weeks old or younger
Expression of MCP-1 under basal, unstressed condi-
tions. As shown in Figure 1 (left), plasma levels of MCP-
1 were markedly increased in HO-1−/− mice, achieving
values that were some fivefold greater as compared with
levels observed in HO-1+/+ mice. To determine the pos-
sible origin for such enrichment of plasma with MCP-
1, production of MCP-1 in assorted tissues was evalu-
ated by determining expression of MCP-1 mRNA by
RT-PCR. Such expression of MCP-1 in HO-1+/+ and
HO-1−/− mice was comparable in tissues such as bone
marrow, aorta, and heart (data not shown). However, as
displayed in Figure 1 (right), MCP-1 mRNA in circulating
leukocytes in HO-1−/− mice, as compared with MCP-1
mRNA expression in HO-1+/+ mice, was increased more
than fivefold. The kidney of HO-1−/− mice exhibited a
fourfold increase in MCP-1 mRNA as compared with the
kidney of HO-1+/+ mice (11.4 ± 2.4 vs. 44.5 ± 18.3) (P
< 0.01) (N = 10 and N = 11, respectively).
This marked elevation in plasma MCP-1 was observed
in HO-1−/− mice even at a younger age. For example,
in 10-week-old mice, plasma concentrations of MCP-1
were increased fivefold in HO-1−/− mice (31.9 ± 3.7 vs.
136.1 ± 15.1 pg/mL) (P < 0.005) (N = 6 in each group).
Thus, plasma levels of MCP-1 are increased in unstressed
HO-1−/− mice as compared to HO-1+/+ mice, and such
markedly increased MCP-1 levels are accompanied by
increased expression of the MCP-1 gene in circulating
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Fig. 2. MCP-1 mRNA in the kidney in HO-1+/+ and HO-1−/− mice at two time points. (Upper) MCP-1 mRNA in the kidney in HO-1+/+ and
HO-1−/− mice subjected to saline vehicle (WT-Veh, N = 3 and KO-Veh, N = 3) or hemoglobin (WT-Hgb, N = 4 and KO-Hgb, N = 4) after 8
hours. (Lower) MCP-1 mRNA in the kidney in HO-1+/+ and HO-1−/− mice subjected to saline vehicle (WT-Veh, N = 3 and KO-Veh, N = 3) or
hemoglobin (WT-Hgb, N = 3 and KO-Hgb, N = 5) after 3 days.
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Fig. 3. MCP-1 mRNA in the kidney by Northern analysis in HO-1+/+ and HO-1−/− mice subjected to insertion of a needle into the tail vein but
no injection of saline (WT-Sham and KO-Sham) and HO-1+/+ and HO-1−/− mice subjected to intravenous injection of saline (WT-Saline and
KO-Saline) after 8 hours (Upper). The numbers below the Northern analysis are the standardized densitometric readings and the mean values for
each group, and are factored for loading variations, the latter assessed by densitometric analysis of ethidium staining of 18S rRNA on the membrane
(Lower).
leukocytes and in the kidney, but not in such tissues as
bone marrow, aorta, and heart.
Expression of MCP-1 in response to a nephrotoxic
insult. We also evaluated changes in MCP-1 expres-
sion in response to a nephrotoxic insult induced by
hemoglobin. These studies were undertaken at an early
time point (8 hours) and at a delayed time point (3 days)
after the administration of a single dose of hemoglobin. In
response to such administration of hemoglobin, and after
8 hours, HO-1+/+ mice exhibited increased expression
of MCP-1 mRNA in the kidney, which completely sub-
sided by 3 days (Fig. 2). The pattern of response in HO-
1−/− mice, however, was markedly different. At 8 hours,
MCP-1 expression was increased in HO-1−/− mice not
only in the hemoglobin-treated HO-1−/− mice but also
in the saline-treated HO-1−/− mice; by 3 days, MCP-1
expression was no longer detected in saline-treated HO-
1−/− mice, whereas MCP-1 expression strongly persisted
in hemoglobin-treated HO-1−/− mice (Fig. 2). Thus, at
an early time point, MCP-1 is elicited in the kidney in
HO-1+/+ mice in response to hemoglobin but not in re-
sponse to saline. However, at an early time point, in HO-
1−/− mice, either treatment induces MCP-1, whereas at
a delayed time point, persisting and striking expression of
MCP-1 is seen only in the hemoglobin-treated HO-1−/−
mice.
To determine whether the stress of simply injecting a
physiologic fluid such as isotonic saline is sufficient to in-
duce MCP-1, we administered an equal volume of sterile,
endotoxin-free, saline to HO-1+/+ and HO-1−/− mice.
As shown in Figure 3, increased expression of MCP-1
mRNA was observed in HO-1−/− mice but not in HO-
1+/+ mice in response to saline.
Expression of MCP-1 and response to renal ischemia.
In view of the recognition of MCP-1 as a contributor to
ischemic acute renal injury [21–24], as well as our find-
ings that MCP-1 is significantly up-regulated in HO-1−/−
mice, we examined renal responses, including expression
of MCP-1, in HO-1+/+ and HO-1−/− mice subjected to
I/R.
HO-1−/− mice exhibited profound sensitivity to I/R
injury. As demonstrated on day 1 after I/R, HO-1−/−
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Fig. 4. Blood urea nitrogen (BUN) (mg/dL) in HO-1+/+ and HO-
1−/− mice subjected to sham ischemia (WT-Sham and KO-Sham) and
HO-1+/+ and HO-1−/− mice subjected to ischemia/reperfusion (IR)
injury (WT-IR and KO-IR). ∗P < 0.05 vs. all other groups.
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Fig. 5. Plasma creatinine (mg/dL) in HO-1+/+ and HO-1−/− mice
subjected to sham ischemia (WT-Sham and KO-Sham) and HO-1+/+
and HO-1−/− mice subjected to ischemia/reperfusion injury (IR) (WT-
IR and KO-IR). ∗P < 0.05 vs. all other groups.
mice subjected to I/R exhibited worse renal function as
assessed by BUN (Fig. 4) and plasma creatinine (Fig. 5).
As added evidence of more marked injury in the kid-
ney in HO-1−/− mice subjected to ischemia, we assessed
the expression in the kidney of a critical participant in
the cell death pathway, namely, caspase-3. As shown in
Figure 6, caspase-3 is markedly increased in the kidney in
HO-1−/− mice. Thus, ischemia provokes exaggerated ex-
pression of the cell death participant, caspase-3, in addi-
tion to the worsening of renal function. Semiquantitative
scores for histologic injury in HO-1+/+ and HO-1−/−
mice showed no significant differences in scores for di-
latation of cortical and medullary tubules (0.60 ± 0.24 vs.
0.57 ± 0.20) (N = 5 and N = 7, respectively) following re-
nal ischemia; scores for tubular necrosis 1 day following
I/R in HO-1+/+ and HO-1−/− mice tended to be, but
were not, significantly higher in HO-1−/− mice (12.0 ±
4.9% vs. 22.1 ± 8.7%) (N = 5 and N = 7, respectively).
Mortality was increased in HO-1−/− mice in response
to I/R within the first day after I/R, and by day 7 after
I/R, cumulative mortality was 63% in the HO-1−/− mice
subjected to ischemia compared to an absence of mortal-
ity in the other groups (Fig. 7). Renal histologic studies
were also performed in mice surviving to day 7. The kid-
neys appeared normal in HO-1+/+ mice 7 days after I/R,
and semiquantitative scores were all zero for dilatation of
cortical and medullary tubules, and for tubular necrosis.
In contrast, the kidneys in HO-1−/− mice demonstrated
prominent dilatation of cortical (1.7 ± 0.7) and medullary
tubules (2.0 ± 0.0), as well as tubular necrosis (16.7 ±
1.7%). Representative sections of the kidney from HO-
1+/+ and HO-1−/− mice 7 days after I/R are shown in
Figure 8.
We also assessed expression of MCP-1 mRNA at day 1
and day 7 after I/R in HO-1+/+ and HO-1−/− mice. Ad-
ditionally, since MCP-1 is regulated by the transcription
factor, NF-jB, which is activated by I/R, we also assessed
expression of NF-jB at 1 hour following ischemia. The
highest expression of NF-jB was observed in the HO-
1−/− mice subjected to I/R (Fig. 9A). The differences
in MCP-1 mRNA expression in the kidney in HO-1+/+
and HO-1−/− mice, observed in the unstressed state, per-
sisted after I/R, as shown in studies undertaken on day 1
(Fig. 9B) and day 7 (Fig. 9C) after I/R.
Studies in aged HO-1+/+ and HO-1−/− mice
In view of the potent chemoattractant actions of MCP-
1 [14, 15], and the up-regulation of this chemokine in the
circulation and kidney of the unstressed HO-1−/− mice,
we examined the kidneys of aged HO-1−/− mice to de-
termine whether inflammatory disease appeared in the
kidneys. As shown in Figure 10, inflammatory changes,
consisting of mononuclear cellular infiltration and
variable amounts of fibrosis, occurred in the tubuloin-
terstitium of HO-1−/− mice. Additionally, glomeruli
exhibited a proliferative glomerulonephritis with exuda-
tive changes in the glomerular loops (Fig. 10); ultrastruc-
tural studies of these kidneys by electron microscopy
failed to reveal the presence of immune deposits in the
glomeruli or elsewhere in the kidneys of HO-1−/− mice
(data not shown). Thus, in aged HO-1−/− mice, inflam-
matory changes accompany the marked up-regulation
of MCP-1 occurring in the kidney. These inflammatory
changes were accompanied by increased gene expression
of fibrosis-related genes, including TGF-b1, and colla-
gens I, III, and IV (Fig. 11).
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Fig. 6. Western analysis for renal expression
of caspase-3 in HO-1+/+ and HO-1−/−
mice subjected to sham ischemia (WT-Sham
and KO-Sham) and HO-1+/+ and HO-1−/−
mice subjected to ischemia/reperfusion (IR)
(WT-IR and KO-IR). Equivalency of loading
was assessed by expression of b-actin.
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Fig. 7. Survival curves for HO-1+/+ and HO-1−/− mice subjected to
ischemia for 15 minutes (N = 6 in the HO-1+/+ group and N = 8 in
the HO-1−/− group). ∗P < 0.05 between the two groups at day 7.
DISCUSSION
Our findings demonstrate that the inability to express
HO-1, as occurs in HO-1−/− mice, is attended by up-
regulation of MCP-1 in unstressed as well as stressed
conditions. Under basal, stress-free conditions, the
HO-1−/− mouse exhibits a fivefold increase in plasma
concentrations of MCP-1, and increased expression of
MCP-1 mRNA in circulating leukocytes and in the kid-
ney. In response to a potentially nephrotoxic insult (such
as a single injection of hemoglobin, which under con-
ditions employed, does not influence renal function in
wild-type mice), or in response to a “physiologic” stim-
ulus (isotonic saline), HO-1−/− mice exhibited either a
persisting or an augmented expression of MCP-1 mRNA
in the kidney. Finally, a quite brief episode of ischemia
(which does not influence renal function in wild-type
mice) elicits expression of MCP-1 mRNA in the ischemic
kidneys of HO-1−/− mice which far outstrips such ex-
pression in HO-1+/+ mice. These findings, in aggregate,
demonstrate that the failure to express HO-1 is attended
by augmented expression of MCP-1, and suggest that the
regulation of MCP-1 is under the tonic suppressive effect
of HO-1. Additionally, in light of the persuasive evidence
for the involvement of MCP-1 in tissue injury—whether
instigated by ischemic, nephrotoxic, or inflammatory in-
sults [14–25]—these findings raise the possibility that the
suppressive action of HO-1 on the expression of MCP-
1 may represent a mechanism whereby the induction of
HO-1 affords protective effects. However, we wish to em-
phasize that our findings regarding heightened expression
of MCP-1 and renal injury in unstressed and stressed HO-
1−/− mice are correlative and not causal in nature; that
such increased expression of MCP-1 may reflect, at least
in part, heightened injury rather than the loss of HO-1 per
se; and that the delineation of the contribution of MCP-1
to renal injury would require additional genetic or other
approaches that modulate the expression of MCP-1.
In our studies, we examined the effects of renal is-
chemia since MCP-1 is not only induced in this condition
but, as recently demonstrated in studies utilizing either
MCP-1 receptor (CCR2) knockout mice or novel strate-
gies which inhibit MCP-1 [22–24], up-regulation of MCP-
1 is a potent contributor to renal ischemic injury. Both at
a relatively early (day 1) and a later time point (day 7)
after an ischemic insult, renal expression of MCP-1 in
HO-1−/− mice was markedly increased as compared
with such renal expression of MCP-1 in HO-1+/+ mice.
HO-1−/− mice were profoundly sensitive to renal is-
chemia as assessed by several indices. First, 1 hour
after renal ischemia, NF-jB, a determinant of MCP-1 ex-
pression and renal injury in the postischemic period [21,
22], exhibited its highest expression in HO-1−/− mice
subjected to ischemia. Second, BUN and plasma creati-
nine were increased more than fourfold and twofold, re-
spectively, in the HO-1−/− mice one day after ischemia,
whereas these indices were essentially unchanged in the
postischemic HO-1+/+ mice. Third, along with these
functional changes on day 1, the kidneys from HO-
1−/− mice subjected to ischemia exhibited the highest
and striking expression of the cell death-related protein,
caspase-3. Fourth, mortality was substantially increased
in HO-1−/− mice subjected to ischemia but did not oc-
cur in other groups. Finally, renal histologic injury was
increased in HO-1−/− mice surviving to 7 days after is-
chemia. Thus, an HO-1 deficiency state, which is attended
by increased renal expression of MCP-1 before and after
renal ischemia, renders the kidney markedly sensitive to
an otherwise innocuous episode of renal ischemia.
This sensitivity of an HO-1 deficiency state to renal is-
chemia is germane to current studies that have explored
the role of HO-1 in renal ischemia. Such studies, uni-
formly utilizing pharmacological competitive inhibitors
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Fig. 8. Histologic appearance of the kidney in HO-1+/+ mice (Left) and HO-1−/− mice (Right) 7 days after ischemia/reperfusion (IR) injury.
Sections were stained with hematoxylin and eosin and are shown at an original magnification of 100×.
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Fig. 9. (A) Expression of the transcription factor, nuclear factor-jB (NF-jB), by electrophoretic mobility shift assay (EMSA) in HO-1+/+ and
HO-1−/− mice subjected to sham ischemia (WT-Sham and KO-Sham) and HO-1+/+ and HO-1−/− mice subjected to ischemia/reperfusion (IR)
injury after 1 hour (WT-IR and KO-IR). (B) MCP-1 mRNA by quantitative real-time RT-PCR in the kidney at day 1 following IR in HO-1+/+
and HO-1−/− mice (WT-IR and KO-IR). ∗P < 0.05. (C) MCP-1 mRNA by quantitative real-time RT-PCR in the kidney at day 7 following IR in
HO-1+/+ and HO-1−/− mice (WT-IR and KO-IR). ∗P < 0.05.
of HO activity, have yielded quite conflicting findings; in-
deed, worsening of renal function [34], improvement of
renal function [35], or no effect on renal function [36],
have all been reported in these studies. While the basis
for these differing conclusions reached by studies that
rely on pharmacologic inhibitors of HO is uncertain at
the present time, it is possible that dose-dependent effects
or nonspecific actions of these competitive inhibitors of
HO activity may be relevant [37]. For example, metal-
loporphyrins employed as inhibitors of HO activity may
exert effects on nitric oxide synthase, guanylate cyclase,
and atrial natriuretic peptide–dependent vasorelaxation
[37]. Our studies using a genetic mutant unable to express
HO-1 demonstrate the exquisite sensitivity of an HO-1
deficiency state to renal ischemia.
Such sensitivity of HO-1−/− mice to renal ischemia
culminated in increased mortality, the latter appearing
within 1 day after ischemia in HO-1−/− mice. At this
time point, renal dysfunction, while clearly worse in HO-
1−/− mice, did not seem severe enough to account for
such mortality, thereby raising the possibility that pro-
cesses at work beyond the confines of the kidney may be
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Fig. 10. Histologic appearance of the kidney in aged (70-week-old) HO-1+/+ mice (left-sided panels) and HO-1−/− mice (right-sided panels).
The upper panels illustrate cortical sections from the kidneys of a HO-1+/+ mouse (left upper panel) and of a HO-1−/− mouse (right upper
panel) at an original magnification of 200×. The lower panels illustrate glomeruli from the kidneys of a HO-1+/+ mouse (left lower panel) and of
a HO-1−/− mouse (right lower panel) at an original magnification of 400×. All sections were stained with hematoxylin and eosin.
involved. In this regard, there is accumulating evidence
that ischemia, imposed just on the kidney, nonetheless,
instigates systemic perturbations and adverse effects on
distant vital organs such as the heart and lung. For ex-
ample, renal ischemia provokes increased vascular per-
meability in the lungs [38], and apoptosis and contractile
dysfunction in the heart [39]. The relay of information
from the ischemic kidney to these vital organs likely in-
volves inflammatory mediators, and in this regard, the ex-
tent to which systemic concentrations of cytokines [such
as interleukin (IL)-6] are elevated in human acute renal
failure correlates with mortality observed in this condi-
tion [40]; additionally, circulating levels of C-reactive pro-
tein (CRP), the latter representing a potent inducer of
IL-6, MCP-1, and other cytokines [41], predict renal and
respiratory failure, and overall mortality in critically ill
patients [42]. While the mechanism underlying increased
mortality in postischemic HO-1−/− mice is beyond the
scope of our present studies, it is possible that the preex-
isting inflammatory state that resides in HO-1−/− mice,
as exemplified by the elevated MCP-1 expression in the
systemic circulation and kidney, may be relevant. It is also
possible that the failure to express HO-1 in vital organs
such as the heart and lungs in HO-1−/− mice may ren-
der these organs especially prone to dysfunctional effects
initiated by renal ischemia.
In view of the marked increase in plasma concen-
trations of MCP-1, and increased MCP-1 mRNA ex-
pression in circulating leukocytes and in the kidney in
relatively younger HO-1−/− mice, we examined whether
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Fig. 11. Collagens I (a1), III (a1), and
IV (a1), and transforming growth factor-b1
(TGF-b1) mRNA expression in the kidneys of
aged (70-week-old) HO-1+/+ and HO-1−/−
mice, as assessed by Northern analysis. The
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mean standardized densitometric readings for
each group.
the kidney in aged mice, protractedly exposed to such lo-
cal and systemic up-regulation of MCP-1, would evince
phenotypic changes consistent with known actions of
MCP-1, a chemokine incriminated in acute prolifera-
tive and chronic inflammatory processes [14–20]. Kid-
neys in aged HO-1−/− mice, in the absence of any
other manipulation, demonstrated proliferative changes
in glomeruli, tubulointerstitial inflammation, and up-
regulation of TGF-b1 and fibrogenic genes. While such
glomerular histologic changes have been described pre-
viously [28], the basis for these changes is unknown; ad-
ditionally, these other renal histologic changes reported
in the present study have not been previously described.
In our studies, we failed to observe evidence of immune
deposits in glomeruli in HO-1−/− mice, thus arguing
against an immune complex process. We speculate that
the heightened expression of MCP-1 in HO-1−/− mice
may be relevant to these changes in glomeruli. Increased
MCP-1 expression may also be relevant to the cellular in-
filtration observed in the tubulointerstitium, and in view
of the recognized inductive effect of MCP-1 on TGF-
b1 [43], MCP-1 may contribute, additionally, to the up-
regulation of TGF-b1 observed in the kidneys of HO-
1−/− mice.
Our findings complement recent and novel studies
that have examined the effect of HO-1 deficiency on
inflammatory responses [44]. In studies undertaken in
splenocytes harvested from HO-1−/− mice, mitogenic
stimulation effected by either lipopolysaccharide or anti-
CD3/anti-CD28, provoked the release of higher amounts
of proinflammatory Th1 cytokines as compared to simi-
larly treated splenocytes from HO-1+/+ mice [44]. Thus,
under stressed conditions, as shown in these studies
[44], the HO-1 deficiency state tilts the cytokine profile
decidedly toward a proinflammatory Th1 pattern. Inter-
estingly, MCP-1, acting through its receptor, CCR2, stim-
ulates Th1 polarization [14, 15], and thus the presence
of increased systemic levels of MCP-1 in the unstressed
state in HO-1−/− mice, as shown in the present studies,
may be germane to the proclivity of stressed HO-1−/−
mice toward Th1 responses. However, as recently shown,
MCP-1, independent of the CCR2 receptor, may also in-
fluence Th2 polarization [14, 15].
CONCLUSION
We demonstrate the seemingly invariant up-regulation
of MCP-1 in an HO-1–deficient state when the latter is
examined not only under several conditions of stress, but
also in the unstressed, unperturbed state, and in such set-
tings, a phenotypic change is observed that is consistent
with, and/or predicted by, known actions of MCP-1. From
these findings, we suggest that the suppressive effects
of HO-1 on the expression of MCP-1 may be a mech-
anism that contributes to the protective actions of HO-1.
We also suggest that our observations may be relevant
to recent clinical observations: deficiency of the HO-1
gene in humans predisposes toward renal and vascular
diseases [45–47]. For example, homozygous deficiency of
HO-1 promotes oxidative stress and incurs the develop-
ment of renal disease [45, 46], whereas polymorphisms
in the HO-1 gene that lead to diminished HO activity,
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predispose toward vascular and other diseases [47]. Given
the intimate involvement of MCP-1 in vascular and renal
disorders, we speculate that in patients with deficiencies
or decrements in HO activity, the attendant up-regulation
in MCP-1 contributes to the proclivity to renal and vas-
cular diseases observed in these patients.
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